BioMonde’s Biosurgical Debridement Product BioBag is Now Available on the VA Federal Supply Schedule (FSS)

BioMonde awarded Federal Supply Schedule contract

BioBag is a fully enclosed net dressing containing the live larvae of the greenbottle fly Lucilia sericata. (Photo: Business Wire)

???pagination.previous??? ???

GAINESVILLE, Fla.--()--BioMonde US, LLC announced that the BioBag product range has been awarded a contract on the Veterans Affairs (VA) Federal Supply Schedule. This successful award comes after BioMonde has been conducting business in the US since the launch of the BioBag in 2014. This contract award enables BioMonde to provide the BioBag product range to the largest integrated healthcare system in the US; the FSS services the VA and other federal government agencies such as the Indian Health Service and the Department of Defense. This means that BioBag is now available to nearly 9 million VA patients of which up to 25% present with diabetes.

BioBag – innovation of an old concept

BioBag is both a clinically and cost effective way for clinicians to treat non-healing wounds such as pressure ulcers, diabetic ulcers, surgical wounds, traumatic wounds and venous stasis ulcers. BioBag contains all the known benefits of Larval Therapy in a quick and easy-to-use contained dressing. Ease of application, rapid debridement times, and economical product costs make BioBag an efficient debridement solution for all non-healing wounds.

Each of the five available sizes in the BioBag product range (BB50, BB100, BB200, BB300 and BB400) have been awarded the contract under Schedule 65 II A – Medical Equipment and Supplies.

BioMonde’s commitment

BioMonde is dedicated to improving outcomes of non-healing wounds within the Veterans Affairs Health System. BioMonde is currently sponsoring a 140 patient clinical trial through the Center of Innovation on Disability and Rehabilitation Research (CINDRR) at the Malcom Randall VA Medical Center in Gainesville, Florida. This outpatient study compares the removal of bacterial biofilm in sharp debridement (control) versus BioBag in non-healing diabetic foot ulcers and leg ulcers.

BioMonde US LLC

CEO Gareth Kempson said that “BioMonde have long known how beneficial BioBag can be for patients within the Veterans Affairs and Indian Health System. We are delighted that this treatment is now available through FSS. We are extremely confident that BioBag can make a significant and positive difference to the treatment of Veterans and patients of the Indian Health Service and assist in not only providing cost effective care and improved clinical outcomes but also by delivering an improvement to the quality of life for them and their family.”

BioMonde have a specialist manufacturing site at the Innovation Hub at the University of Florida in Gainesville. BioMonde secured financial backing from Finance Wales and Oxford Capital in 2014 after the European company received FDA 510(k) approval for the patented debridement product BioBag. BioBag is available nationally with local product support available in most major cities within the US.

You can find the BioBag FSS catalog listing here.

For more information about BioBag please visit or call 1.844.434.8529.

Caution: Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.

Note: Information on the warnings, side effects, indications and contraindications can be found by visiting


BioMonde, LLC
Katy Nicell, 352-294-7162

Release Summary

BioMonde's wound debridement product BioBag has been awarded a contract on the Federal Supply Schedule (FSS).


BioMonde, LLC
Katy Nicell, 352-294-7162